|
IN8bio, Inc. (INAB): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
IN8bio, Inc. (INAB) Bundle
In the cutting-edge world of cancer immunotherapy, IN8bio, Inc. is pioneering a revolutionary approach to treating solid tumors through innovative gamma delta T-cell therapies. This emerging biotech company is transforming precision medicine by developing patient-specific cell treatments that could potentially redefine cancer treatment strategies. With their lead product candidate INAB-200 targeting glioblastoma multiforme and a strategic focus on advanced immunological mechanisms, IN8bio represents a beacon of hope in the complex landscape of oncological research and targeted therapeutic interventions.
IN8bio, Inc. (INAB) - Marketing Mix: Product
Innovative T-Cell Immunotherapies
IN8bio develops gamma delta T-cell therapies targeting solid tumors with precision medicine approach.
Lead Product Candidate: INAB-200
INAB-200 is specifically designed for glioblastoma multiforme treatment, currently in clinical development.
| Product Characteristic | Specific Details |
|---|---|
| Therapy Type | Gamma Delta T-cell Immunotherapy |
| Primary Target | Solid Tumor Cancers |
| Lead Indication | Glioblastoma Multiforme |
| Clinical Stage | Phase 1/2 |
Product Development Characteristics
- Patient-specific cell therapy approach
- Unique immunological mechanism of action
- Precision medicine targeting
Clinical Pipeline
| Product | Indication | Development Stage |
|---|---|---|
| INAB-200 | Glioblastoma | Phase 1/2 |
| INAB-400 | Ovarian Cancer | Preclinical |
IN8bio, Inc. (INAB) - Marketing Mix: Place
Headquarters Location
420 Lexington Avenue, 21st Floor, New York City, New York 10170
Clinical Trial Locations
| State | Number of Medical Centers |
|---|---|
| New York | 3 |
| California | 2 |
| Texas | 1 |
| Massachusetts | 2 |
Market Distribution Channels
- Oncology treatment centers
- Academic research institutions
- Specialized cancer clinics
Geographical Market Focus
North American Market Coverage
- United States primary market
- Potential expansion into Canadian oncology markets
Collaborative Research Partnerships
| Institution Type | Number of Partnerships |
|---|---|
| Academic Medical Centers | 5 |
| Cancer Research Institutes | 3 |
| Biotechnology Research Centers | 2 |
Precision Immunotherapy Sector Presence
Emerging Biotech Sector Positioning
- Focused on gamma delta T cell therapy development
- Targeting glioblastoma and other solid tumor treatments
IN8bio, Inc. (INAB) - Marketing Mix: Promotion
Presenting at Oncology and Immunotherapy Medical Conferences
IN8bio participated in the following key medical conferences in 2023:
| Conference | Date | Location | Presentation Focus |
|---|---|---|---|
| American Society of Hematology (ASH) Annual Meeting | December 2023 | San Diego, CA | DNAr T-cell therapy for GBM |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | San Diego, CA | Precision immunotherapy research |
Engaging Investors through Scientific Presentations and Earnings Calls
Investor communication metrics for 2023:
- 4 quarterly earnings calls
- 2 investor conference presentations
- Market capitalization: $62.41 million (as of January 2024)
Publishing Research Findings in Peer-Reviewed Medical Journals
| Journal | Publication Date | Research Topic |
|---|---|---|
| Nature Medicine | September 2023 | DNAr T-cell therapy clinical trial results |
| Journal of Immunotherapy | November 2023 | Precision immunotherapy mechanisms |
Utilizing Digital Platforms to Communicate Scientific Advancements
Digital communication channels:
- Twitter followers: 3,427
- LinkedIn connections: 2,985
- Website unique monthly visitors: 15,672
Developing Investor Relations and Scientific Communication Strategies
Communication strategy focus areas:
- Transparency in clinical trial progress
- Regular scientific updates
- Investor engagement through detailed financial reporting
IN8bio, Inc. (INAB) - Marketing Mix: Price
Financial Overview
As of Q4 2023, IN8bio reported: • Cash and cash equivalents: $39.7 million • Net loss: $24.4 million for the fiscal year • Research and development expenses: $16.5 million
Stock Performance
| Stock Metric | Value |
|---|---|
| NASDAQ Ticker | INAB |
| Stock Price (as of January 2024) | $1.23 |
| Market Capitalization | $45.2 million |
Funding and Valuation
Venture Capital Funding Breakdown
- Total venture capital raised: $87.6 million
- Key investors: Perceptive Advisors, Cowen Healthcare Investments
- Series B funding round: $55 million in 2021
Pricing Strategy Considerations
| Pricing Factor | Current Status |
|---|---|
| Clinical Stage Therapies | Phase 1/2 trials for GD2-targeted immunotherapies |
| Potential Treatment Areas | Glioblastoma, Neuroblastoma |
| FDA Approval Status | Pending clinical trial results |
Research and Development Investment
R&D Expenditure Trend
- 2022 R&D expenses: $16.2 million
- 2023 R&D expenses: $16.5 million
- Projected 2024 R&D budget: Approximately $18-20 million
Financial Projections
As a pre-revenue biotechnology company, IN8bio's pricing strategy remains contingent on future clinical trial outcomes and potential market positioning of its immunotherapy technologies.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.